N/A
N=28
Event Marker Ingested To Trigger Event Recorder 3.0 Psychiatry Study
Bipolar Disorder · Schizophrenia
Bottom Line
View on ClinicalTrials.gov: NCT01804257 ↗Enrolled (actual)
28
Serious AEs
3.6%
Results posted
Jun 2017
Primary outcome: Primary: Positive Detection Accuracy — 94 percentage of observed ingestions
Study Design & Population
- Study type
- Interventional
- Phase
- N/A
- Interventions
- Digital Health Feedback System (Other)
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- All
- Sponsor
- Proteus Digital Health, Inc.
- Primary completion
- May 2011
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Positive Detection Accuracy |
94 | — |
| SECONDARY System Safety |
— | — |
Summary
Feasibility study of using a digital health feedback system (DHFS) to monitor medication-taking and physiologic and behavioral parameters in patients with bipolar disorder or schizophrenia. Hypothesis: Using a digital health feedback system to characterize medication-taking behavior and activities of daily living is safe and tolerable in appropriately selected patients with bipolar disorder and schizophrenia.
Eligibility Criteria
Inclusion Criteria
- Male or female ≥ 18 and ≤ 65 years of age
- Meet Diagnostic and Statistical Manual of Mental Disorders (DSM-IV) criteria, by Structured Clinical Interview using DSM-IV SCID-I/P1, for either:
i. Bipolar disorder I, II, or Not Otherwise Specified (NOS), or ii. Schizophrenia or schizoaffective disorder
- Clinical global impression scale-severity (CGI-S) of 3 or below
- Currently on a stable regimen of oral antimanic or antipsychotic medication for at least 3 months
- No anticipation to change or titrate the regimen in the next 28 days
- Willingness to adhere to study procedures
- Capacity to provide informed consent
Exclusion Criteria
- Pregnancy, or women of child bearing potential who are not using a medically accepted means of contraception
- Serious suicide or homicide risk, as assessed by evaluating clinician
- Unstable medical illness including cardiovascular, hepatic, renal, respiratory, endocrine, neurological, or hematological disease
- DSM-IV diagnoses or symptoms of substance use disorders, active within the last 60 days
- A score of 3 or higher on the suspiciousness/paranoia item of the Brief Psychiatric Rating Scale (BPRS)
- Acute, clinically significant gastrointestinal symptoms, such as nausea, vomiting, abdominal pain, diarrhea, melena, or hematochezia
- History of significant gastrointestinal disease or major gastrointestinal surgery
- Clinical instability of any kind that, in the investigator's opinion, could preclude safe participation in the study
- Known allergies that could preclude safe participation in the study
- Current presence of an electronically active implanted medical device
- Participation in another medical device study, or on any investigational drug or device within the last 30 days
- Inability to obtain consent
Data sourced from ClinicalTrials.gov (NCT01804257). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.